These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18161146)

  • 1. [New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].
    Endo I; Matsumoto T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():443-6. PubMed ID: 18161146
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y; Wakayama N; Miyauchi A
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of osteoporosis with PTH].
    Takeuchi Y
    Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
    N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [FACT study].
    Tanaka I; Oshima H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():280-5. PubMed ID: 18161120
    [No Abstract]   [Full Text] [Related]  

  • 7. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
    Sowa H; Hamaya E; Yamamoto T
    Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
    Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contribution of bone quality to fracture risk].
    Mori S
    Clin Calcium; 2004 Oct; 14(10):33-8. PubMed ID: 15577129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
    Kishimoto H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evidence and utility of etidronate for the treatment of osteoporosis].
    Takada J; Iba K; Yamashita T; Yoshizaki T
    Clin Calcium; 2008 Oct; 18(10):1427-33. PubMed ID: 18830039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Process in development of PTH, an awaited bone-density conservation agent].
    Sugimoto T
    Clin Calcium; 2012 Mar; 22(3):307. PubMed ID: 22893932
    [No Abstract]   [Full Text] [Related]  

  • 18. [Evidence for efficacy of active vitamin D3 as an anti-osteoporotic drug].
    Inoue D
    Clin Calcium; 2008 Oct; 18(10):1469-75. PubMed ID: 18830044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [hPTH(1-34) injection].
    Uzawa T; Yamauchi H
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():548-54. PubMed ID: 15035188
    [No Abstract]   [Full Text] [Related]  

  • 20. [Lumbar bone density].
    Winter EF
    Dtsch Med Wochenschr; 1998 Dec; 123(50):1532-3. PubMed ID: 9879285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.